FDA Licenses a Second Biosimilar – The Parameters of Approval Come Into Better Focus

FDA Licenses a Second Biosimilar – The Parameters of Approval Come Into Better Focus

Submitted by admin on April 7, 2016 - 9:49am
Source: 
FDA Law Blog
News Tags: 
FDA
biosimilars
JNJ
Remicade
Inflectra
Pfizer
Celltrion
Headline: 
FDA Licenses a Second Biosimilar – The Parameters of Approval Come Into Better Focus

Do Not Allow Advertisers to Use My Personal information